Imperial College London
Alternate

DrRaffaelePalladino

Faculty of Medicine, School of Public Health

Visiting Professor
 
 
 
//

Contact

 

r.palladino Website

 
 
//

Location

 

309Reynolds BuildingCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Petruzzo:2021:10.1111/ene.14608,
author = {Petruzzo, M and Reia, A and Maniscalco, GT and Luiso, F and Lanzillo, R and Russo, CV and Carotenuto, A and Allegorico, L and Palladino, R and Brescia, Morra V and Moccia, M},
doi = {10.1111/ene.14608},
journal = {European Journal of Neurology},
pages = {893--900},
title = {The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis},
url = {http://dx.doi.org/10.1111/ene.14608},
volume = {28},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background and purposeCardiovascular risk factors and comorbidities can affect the prognosis of multiple sclerosis (MS). The Framingham risk score is an algorithm that can estimate the 10year risk of developing macrovascular disease. Our objectives were to evaluate the possible association between the Framingham risk score at baseline and MS relapses, disability, and diseasemodifying therapy (DMT) choices over a 5year followup.MethodsThis is a retrospective cohort study including 251 MS subjects. At baseline, we calculated the Framingham risk score considering the following variables: age, sex, diabetes, smoking, systolic blood pressure, and body mass index. MS outcomes including relapses, disability, and treatments were collected over 5 years. Cox proportional regression models were employed to estimate hazard ratios (HRs).ResultsA onepoint increase in the Framingham risk score was associated with 31% higher risk of relapse (HR = 1.31; 95% confidence interval [CI] = 1.03, 1.68), 19% higher risk of reaching of EDSS 6.0 (HR = 1.19; 95% CI = 1.05, 3.01), and 62% higher risk of DMT escalation (HR = 1.62; 95% CI = 1.22, 3.01).ConclusionsHigher cardiovascular risk was associated with higher risk of relapses, disability, and DMT escalation in MS. Early identification, correction, and treatment of cardiovascular comorbidities should be carefully considered within MS management.
AU  - Petruzzo,M
AU  - Reia,A
AU  - Maniscalco,GT
AU  - Luiso,F
AU  - Lanzillo,R
AU  - Russo,CV
AU  - Carotenuto,A
AU  - Allegorico,L
AU  - Palladino,R
AU  - Brescia,Morra V
AU  - Moccia,M
DO  - 10.1111/ene.14608
EP  - 900
PY  - 2021///
SN  - 1351-5101
SP  - 893
TI  - The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis
T2  - European Journal of Neurology
UR  - http://dx.doi.org/10.1111/ene.14608
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000591078500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://onlinelibrary.wiley.com/doi/10.1111/ene.14608
UR  - http://hdl.handle.net/10044/1/85393
VL  - 28
ER  -
Download